NOVELTY - A protein comprising an amino sequence selected from SEQ ID NO. 2-7 or an amino acid sequence having at least 75% sequence identity to SEQ ID NO. 2-7 is new.    USE - The protein and composition are useful for producing a biofuel; cleaning, disinfecting or sterilizing an inert surface; improving delivery of an intravenous composition; and treating, preventing or inhibiting a disease, disorder or condition marked by the presence of biofilra or by an abnormal level of hyaluronic acid. The disease, disorder or condition marked by the presence of biofilra is selected from a urinary tract infection, a catheter-originated infection, a middle-ear infection, dental plaque, gingivitis, an eye infection, endocarditis, cystic fibrosis, and nosocomial infections. The disease, disorder or condition marked by an abnormal level of hyaluronic acid is a disease, disorder or condition of the epithelial, connective or neural tissue. The disease, disorder or condition marked by an abnormal level of hyaluronic acid is cancer (all claimed).    ADVANTAGE - Thermally stable enzymes are provided.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are:    (1) a composition comprising a protein comprising an amino sequence selected from SEQ ID NO. 2-7; and a carrier;    (2) a nucleic acid molecule comprising SEQ ID NO. 1;    (3) a method of producing a biofuel by contacting a hydrolysate with a protein comprising an amino acid sequence selected from SEQ ID NO. 2-7;    (4) a method of cleaning, disinfecting or sterilizing an inert surface by contacting the surface with a protein comprising an amino acid sequence selected from SEQ ID NO. 2-7;    (5) a method of treating, preventing or inhibiting a disease, disorder or condition marked by the presence of biofilra or by an abnormal level of hyaluronic acid by administering a protein comprising an amino acid sequence selected from SEQ ID NO. 2-7 to a body surface of a patient; and    (6) a method of improving delivery of an intravenous composition by contacting an injection site of a subject with a protein comprising an amino acid sequence selected from SEQ ID NO. 2-7, and administering an intravenous composition to the subject via the injection site.